3/15
08:30 am
mxct
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price [Seeking Alpha]
Medium
Report
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price [Seeking Alpha]
3/12
09:11 am
mxct
MaxCyte, Inc. (NASDAQ: MXCT) was given a new $6.00 price target on by analysts at BTIG Research. They now have a "buy" rating on the stock.
Low
Report
MaxCyte, Inc. (NASDAQ: MXCT) was given a new $6.00 price target on by analysts at BTIG Research. They now have a "buy" rating on the stock.
3/12
08:05 am
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at Stifel Nicolaus from $11.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at Stifel Nicolaus from $11.00 to $9.00. They now have a "buy" rating on the stock.
3/11
07:54 pm
mxct
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript [Seeking Alpha]
3/11
04:54 pm
mxct
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance [Yahoo! Finance]
Low
Report
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance [Yahoo! Finance]
3/11
04:05 pm
mxct
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
Medium
Report
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
2/12
03:58 am
mxct
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs [Yahoo! Finance]
Low
Report
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs [Yahoo! Finance]
2/12
02:00 am
mxct
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
Low
Report
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
2/7
02:00 am
mxct
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
Low
Report
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
1/30
10:36 am
mxct
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
Medium
Report
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
1/30
02:00 am
mxct
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
Low
Report
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
1/13
03:05 am
mxct
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
High
Report
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results